Background: Longitudinal assessment of liver fibrosis with transient elastometry (TE) in patients with chronic viral hepatitis is becoming routine clinical practice in many clinics, as this procedure is non-invasive, easy to perform and relatively inexpensive, allowing early detection of cirrhosis. Herein, we examine the incidence of cirrhosis, using TE assessment, in HIV-infected individuals with chronic hepatitis B or C receiving highly active antiretroviral therapy (HAART). Methods: A longitudinal study was performed on a cohort of HIV-infected patients with chronic hepatitis B or C who were followed since 2004 at Hospital Carlos III (Madrid, Spain) with periodic TE assessments. The primary outcome was the development of cirrhosis, defined as liver stiffness >12.5 KPa. Results: A total of 508 HIV-infected patients were examined, of whom 54 developed liver cirrhosis during a mean ±sd follow-up of 2.6 ±1.0 years (overall incidence was 41.13 cases per 1,000 person-years). The risk of developing cirrhosis was significantly higher in 297 HCV-RNA-positive patients (either untreated or non-responders to hepatitis C therapy) compared with 55 patients who had cleared HCV with therapy (odds ratio 3.73, 95% confidence interval 1.06-13.17; P=0.04). By contrast, the risk of developing cirrhosis was low and similar in 24 HIV-HBV-coinfected patients under long-term suppressive HBV therapy (mainly tenofovir disoproxil fumarate), 132 HIV-infected patients without chronic liver disease and those who had cleared HCV with therapy. Conclusions: Development of liver cirrhosis in HIV-infected individuals in the HAART era is mainly associated with active HCV coinfection. The risk of developing cirrhosis is negligible in patients who cleared HCV with therapy, as well as in HIV-HBV-coinfected patients on long-term suppressive tenofovir disoproxil fumarate therapy.
Since the advent of highly active antiretroviral therapy (HAART) in the late 1990s, liver-related mortality has steadily become one of leading causes of non-AIDSrelated death in HIV-infected individuals [1] . With large variability depending on the prevalence of risk factors for liver disease, approximately 8-18% of HIV-infected individuals might currently have liver cirrhosis, and chronic viral hepatitis is generally the most common cause [2] [3] [4] . Coinfection with HIV leads to faster liver fibrosis progression in patients with chronic viral hepatitis [2, 5, 6] , especially in those with low CD4 + T-cell counts, although fibrosis does not seem to normalize completely in patients on successful HAART and with recovered CD4 + T-cell counts [7, 8] . The mechanisms underlying the accelerated liver fibrosis progression characteristically seen in HIV-infected individuals with chronic viral hepatitis are not well understood, although HIV itself, immunodeficiency and/or antiretroviralrelated toxicity might play a role [9] [10] [11] [12] .
Although some antiretrovirals have been implicated in liver damage [13] [14] [15] [16] , it is clear that the use of HAART diminishes liver-related deaths and improves survival in HIV-infected patients with chronic viral hepatitis [17, 18] . Cohort studies have demonstrated a reduction in the hepatic necroinflammatory activity and a reduction in liver disease in patients receiving HAART [19] .
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Introduction
Besides the use of HAART for minimizing the deleterious effect of HIV infection with regards to liver damage in patients with chronic viral hepatitis, treatment of either HBV or HCV infection with hepatitis-specific antivirals has been demonstrated to significantly reduce liver fibrosis progression, development of hepatic events and mortality [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . A halt or even regression of liver fibrosis might be recognized in the subset of patients who keep HBV persistently suppressed [20, 21] or clear HCV following a course of treatment with pegylated interferon plus ribavirin [25] [26] [27] [28] [29] .
Cirrhosis is the final step of liver fibrosis progression and its diagnosis is crucial in patients with chronic liver disease. The recent availability of non-invasive tools to estimate liver fibrosis has allowed us to circumvent the limitations of liver biopsy as a procedure for staging hepatic fibrosis [30] . Transient elastometry (TE) is increasingly becoming the standard method to longitudinally assess liver fibrosis in patients with chronic liver disease, demonstrating good concordance with histology, especially for the diagnosis of advanced liver fibrosis stages [31] . In HIV-infected patients with chronic viral hepatitis, accuracies >90% have been reported for diagnosing cirrhosis when stiffness values are above certain thresholds [32, 33] . The aim of this study was to examine the progression of liver fibrosis to cirrhosis in a large group of HIV-infected individuals with chronic hepatitis B or C, and the effect of HAART on this progression.
Methods

Study population
A longitudinal retrospective study was conducted on a cohort of HIV-infected patients during regular followup at one large HIV outpatient clinic in Madrid, Spain, who had undergone at least two separate liver fibrosis examinations using TE between October 2004 and February 2009. Patients with a diagnosis of cirrhosis at entry were excluded. Demographics, and clinical and laboratory information, were obtained from computerized medical registers. Records of alcohol abuse (daily intake >50 g/dl during at least the last 4 weeks) were based on medical records.
Patients were classified into four main groups: HIV-HCV-coinfected patients who either never had been exposed to HCV therapy or had failed interferon-based treatment; HIV-HCV-coinfected patients who had cleared HCV following a course of HCV treatment in the past; HIV-HBV-coinfected patients; and HIV-positive patients with no evidence of chronic liver disease.
Liver fibrosis assessment
Transient elastometry (FibroScan ® ; Echosens, Paris, France) was performed following the manufacturer's instructions [34] . Briefly, a minimum of 10 valid measurements through an intercostal space on the right lobe of the liver were obtained. Patients were placed in supine decubitus position with the right arm in abduction; then, the probe of the system was applied between the ribs. The median value was assumed to be representative of liver stiffness and median liver stiffness values were expressed in KPa. A set of measurements was considered to be reliable if the success rate was ≥70% and the interquartile range was less than one-third of the median liver stiffness value. Unreliable measurements were excluded from the analyses. All measurements were obtained from three trained operators using a single device.
The primary outcome was the development of liver cirrhosis in HIV-infected patients with prior liver stiffness values <12.5 KPa. In prior studies, this threshold in liver stiffness has shown an accuracy of 92% for diagnosing cirrhosis, with a negative predictive value of 96% and a positive predictive value of 74% [31] . Liver stiffness values <7.0 KPa, between 7.1 and 9.4 KPa, and between 9.5 and 12.5 KPa were considered as corresponding to Metavir scores F0-F1, F2 and F3, respectively [31] .
Laboratory evaluation
All patients had standard laboratory assessments performed by licensed clinical laboratories, including a complete blood cell count, serum chemistry panels, alanine aminotransferase (ALT) and aspartate aminotransferase levels, CD4 + T-cell counts and plasma HIV RNA levels. Serum hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) were analysed by commercial enzyme immunoassays using AxSYM ® HBsAg (version 2), AxSYM ® HBeAg (version 2) and AxSYM ® anti-HBe (Abbott Laboratories, North Chicago, IL, USA). Total hepatitis delta virus antibodies were analysed using a commercial enzyme immunoassay (Radim Iberica, Barcelona, Spain). Serum HBV DNA and HCV RNA extraction was carried out using the Qiagen DNA kit (Qiagen, Mannheim, Germany), following manufacturer's instructions. Serum HBV DNA and HCV RNA were measured using real-time PCR assays (Cobas ® TaqMan ® ; Roche Molecular Diagnostics, Barcelona, Spain), which have a lower detection limit of 10 IU/ml for either nucleic acid. HBV and HCV genotyping were performed using Inno-Lipa (Innogenetics, Ghent, Belgium).
Statistical analyses
Descriptive statistics were expressed as mean and standard deviations. Multivariate logistic regression analyses were performed to calculate the odds ratio (OR) and 95% confidence intervals (CIs) for developing cirrhosis. The main variables included in this analysis were hepatitis virus coinfection and HCV clearance following interferon-based therapy. The model was adjusted for relevant baseline characteristics, including age, gender, ALT level, CD4 + T-cell count, CD4 + T-cell nadir, plasma HIV RNA, alcohol abuse, intravenous drug use and baseline liver stiffness. Of these, the most significant variables were examined by a multivariate stepwise logistic regression, using P-values for entry and exit of <0.05 and >0.10, respectively. Based on these criteria, baseline liver stiffness values and ALT levels were included in the analyses. The SPSS software package version 15.0 (SPSS, Inc., Chicago, IL, USA) was used in all instances. All tests were two-tailed with P-values <0.05 considered as significant.
Results
Study population
A total of 2,168 HIV-infected patients comprised the original HIV cohort established in 2004. From among them, prospective evaluation using TE with at least two measurements was available for 672 patients. At entry, 164 of these patients already had cirrhosis and were excluded from further analysis. Thus, the study population included 508 HIV-infected patients. The mean ±sd time between the first and last TE examination was 2.6 ±1.0 years. The main baseline characteristics of the study population are shown in Table 1 . It must be noted that the proportion of HIV-HCV-coinfected patients in this cohort who had undergone a liver biopsy was very low (<5%). No adequate comparison between TE and histology could be made given the long time between both tests in most instances.
Incidence of liver cirrhosis
A total of 54 out of 508 (10.6%) patients developed cirrhosis during the study period, which represents an overall incidence of cirrhosis of 41.13 cases per 1,000 person-years. Patients with chronic hepatitis C who had never been treated or who had failed therapy had >2.5-fold greater incidence of cirrhosis than HCVseropositive individuals who had cleared the virus following a course of interferon-based therapy ( (Table 2 ). It should be noted that progression to cirrhosis in these patients was almost always associated with concomitant alcohol abuse, which we defined as a daily intake >50 g during the previous month.
Univariate and multivariate logistic regression analyses adjusted by baseline liver stiffness and ALT values were performed to measure the effect of HCV replication on liver cirrhosis progression ( Table 2 ). The risk of developing liver cirrhosis was significantly higher in HCV viraemic patients (either untreated patients or patients who had failed therapy) than in patients who cleared the virus following HCV therapy (P=0.04). By contrast, HIV-HBV-coinfected patients with suppressed viral replication under therapy (mainly with tenofovir disoproxil fumarate) displayed a low and similar risk of developing cirrhosis than HIV-infected control patients without chronic viral hepatitis. Moreover, there were no significant differences in the risk of developing cirrhosis when comparing these two groups with the subset of patients who cleared HCV with therapy. Finally, in this model, baseline liver stiffness was independently associated with the risk of developing cirrhosis (OR 1.55, 95% CI 1.35-1.89; P<0.001), whereas ALT values were not (OR 1.00, 95% CI 0.99-1.08; P=0.09).
Discussion
The advent of potent antiretroviral therapy has modified the main causes of morbidity and mortality in HIV-infected patients. Non-AIDS conditions are now replacing opportunistic infections and malignancies as the majority of infected patients no longer show advanced immunodeficiency [35] . Liver disease and cardiovascular events are currently among the most frequent causes of hospitalization and death in HIV-infected individuals under regular medical care [1] . Hepatic complications in particular are seen in patients with underlying chronic viral hepatitis. In our study we showed that chronic hepatitis C, but not chronic hepatitis B, is the main factor responsible for the unfavourable outcome. Moreover, control of HBV replication with potent antivirals, such as tenofovir disoproxil fumarate, and clearance of HCV with interferon-based therapies seem to largely counteract the progression of liver fibrosis to cirrhosis in the coinfected population in such a way that HIV-HCV-coinfected patients who have not been treated or who failed therapy are, for the most part, the patients currently progressing to cirrhosis.
Our results are in line with recent data that highlight that serum HBV DNA level is the main driver of the natural history of chronic hepatitis B, with a positive correlation between baseline viral load and risk for developing cirrhosis in the long-term [36] . Accordingly, prolonged complete suppression of HBV viraemia with antiviral therapy might result in a halt and/ or regression of liver fibrosis in HBsAg-positive carriers [20, 21] . Similarly, clearance of HCV following a course of interferon-based therapy seems to be associated with an amelioration or even reversion of liver fibrosis and reduced incidence of liver complications in chronic hepatitis C patients [23] [24] [25] [26] [27] [28] [29] .
Although the widespread use of tenofovir disoproxil fumarate as part of HIV therapy [37] and its success as an anti-HBV agent [38, 39] might have resulted in a broad control of HBV-related disease in HIV-HBV-coinfected patients, the situation is completely different in chronic hepatitis C. Treatment with pegylated interferon plus ribavirin is prescribed in only a small proportion of HIV-HCV-coinfected individuals [40, 41] ; furthermore, HCV clearance is obtained in only 25-40% of treated patients [42] [43] [44] . Altogether, it explains that progression to cirrhosis in HIV-infected individuals largely concentrate in those coinfected with HCV instead of HBV. While waiting for new and more effective treatments against HCV in this population [45] , efforts to identify patients who might benefit from current therapy must be encouraged. In this regard, the recent identification of a genetic marker of treatment response to pegylated interferon plus ribavirin might be very helpful [46] [47] [48] [49] . Moreover, avoidance of potentially hepatotoxic drugs, including some antiretroviral agents (for example, didanosine and stavudine) [11, 14, 15] , adequate management of metabolic abnormalities (for example, dislipidaemias and insulin resistance) that might accelerate liver damage [11, 16, 50, 51] and strong advice against alcohol abuse are warranted. Of note, in our study, progression to cirrhosis in patients without chronic viral hepatitis was rare and mainly seen in association with alcohol abuse.
In summary, the incidence of cirrhosis in HIV-infected patients in the HAART era is mainly associated with HCV coinfection. Although the advent of new antivirals against HCV will fuel treatment of this population, the current data support that in the absence of contraindication for pegylated interferon and/or ribavirin use, treatment of chronic hepatitis C must be pursued in this population. It is very encouraging that HCV clearance following a successful course of interferon-based therapy, as well as prolonged HBV suppression with potent antivirals, such as tenofovir disoproxil fumarate, are both associated with a halt or even reversion of liver fibrosis in patients with chronic viral hepatitis and HIV coinfection.
